Clinical Trials

78 enrolled

Advanced Gastric Cancer

NCT07517653 2026-04-08

Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma

70 enrolled

Dermatologic

Melanoma

NCT07503639 2026-03-31

Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer

134 enrolled

Locally Advanced Colorectal Cancer

NCT07464756 2026-03-11

SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer

80 enrolled

Gastric Adenocarcinoma

NCT07451795 2026-03-05

SHARP

66 enrolled

Genitourinary

Prostatic Neoplasms

NCT05671822 2026-02-12

Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer

258 enrolled

HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

NCT07355010 2026-01-21

A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer

104 enrolled

Gynecologic

Ovarian Neoplasms

NCT07311408 2025-12-31

SHR-2554

40 enrolled

Stomach Neoplasms

NCT07175220 2025-11-18

Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects

200 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07102901 2025-09-10

Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma

351 enrolled

Stomach Neoplasms

NCT05149807 2025-08-20

Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer

Phase 2/3 Terminated

81 enrolled

Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer

NCT06893887 2025-07-02

ICT-HCC

Phase NA Recruiting

300 enrolled

Carcinoma, Hepatocellular

NCT05179239 2025-04-15

A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer

Phase 3 Terminated

31 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT06881017 2025-03-18

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

140 enrolled

Stomach Neoplasms

NCT06679673 2024-11-07

SHR-1701 Combined with SHR2554 and BP102 for MCRC

20 enrolled

Colorectal Cancer Metastatic

NCT04624217 2024-01-11

A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer

Phase 1/2 Completed

56 enrolled

Pancreatic Neoplasms

NCT04407741 2023-12-12

Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas

Phase 1/2 Unknown

100 enrolled

Lymphoid

Lymphoma

NCT05896046 2023-06-15

SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma

Phase 1/2 Recruiting

100 enrolled

Lymphoid

Hodgkin Disease, Recurrence

NCT04699968 2023-06-07

A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT05106023 2023-06-07

To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced Melanoma

31 enrolled

Dermatologic

Melanoma

NCT04580498 2023-05-19

A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC

107 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04324814 2023-02-21

A Trial of SHR-1701 in Subjects With Advanced Solid Tumors

Phase 1 Completed

41 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT03774979 2022-11-08

SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors

Phase 1/2 Not yet recruiting

193 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05503888 2022-08-17

Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

160 enrolled

Recurrence

NCT04355858 2022-07-26

MULAN

319 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT05198817 2022-06-28

A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients

240 enrolled

Advanced Malignant Tumors

NCT04679038 2022-01-26

A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors

Phase 1/2 Unknown

222 enrolled

Other solid neoplasm

Solid Tumor

NCT05177497 2022-01-04

SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC

19 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04282070 2021-12-21

SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

91 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05132413 2021-11-24

A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer

Phase 3 Unknown

561 enrolled

Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer

NCT03710265 2021-11-22

SHR-1701 in Metastatic or Locally Advanced Solid Tumors

206 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04650633 2021-10-29

SHR-1701 in Patients With Recurrent/Metastatic Scchn

130 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05020925 2021-08-25

SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 1/2 Unknown

30 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04884009 2021-05-12

A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung Cancer

106 enrolled

Lung Neoplasms

NCT04560244 2020-09-23

A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment

15 enrolled